VYNE Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 16:00):

Stats
Today's Volume	34 383.00
Average Volume	103 548
Market Cap	36.94M
EPS	$0 ( 2024-03-14 )
Next earnings date	( $-0.240 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.960
ATR14	$0.0190 (0.72%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Zeronda Tyler	Sell	94	Common Stock
2024-04-01	Stuart Iain	Sell	157	Common Stock
2024-04-01	Harsch Mutya	Sell	161	Common Stock
2024-04-01	Domzalski David	Sell	1 004	Common Stock
2024-01-01	Zeronda Tyler	Buy	62 500	Common Stock

INSIDER POWER
-56.80
Last 99 transactions
Buy: 3 356 313 \| Sell: 7 897 303

Volume Correlation

Long: -0.10 (neutral)

Short: 0.35 (neutral)

Signal:(45.941) Neutral

VYNE Therapeutics Inc. Correlation

10 Most Positive Correlations
ALBO	0.962
CMPI	0.962
OCSL	0.934
PALT	0.913
IRMD	0.911
PLRX	0.91
MLAC	0.905
ANDE	0.905
NATI	0.903
DRNA	0.902

10 Most Negative Correlations
CFV	-0.951
AKAM	-0.888
BNIXU	-0.882
GMII	-0.88
TUEM	-0.874
EAR	-0.85
SHLD	-0.845
TRMK	-0.84
DTSS	-0.838
VIVE	-0.837

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

VYNE Therapeutics Inc. Correlation - Currency/Commodity

-0.87
( strong negative )

-0.91
( very strong negative )

0.00
( neutral )

-0.91
( very strong negative )

0.53
( weak )

0.59
( weak )

VYNE Therapeutics Inc. Financials

Annual	2023
Revenue:	$424 000
Gross Profit:	$424 000 (100.00 %)
EPS:	$-2.77

FY	2023
Revenue:	$424 000
Gross Profit:	$424 000 (100.00 %)
EPS:	$-2.77

FY	2022
Revenue:	$477 000
Gross Profit:	$477 000 (100.00 %)
EPS:	$-10.65

FY	2021
Revenue:	$14.76M
Gross Profit:	$11.41M (77.31 %)
EPS:	$-1.420

Financial Reports:

No articles found.

VYNE Therapeutics Inc.

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

Realtime updates for VYNE Therapeutics Inc. [VYNE]

Upcoming Earnings Alert